FORT LAUDERDALE, Fla. — Aflibercept 8 mg demonstrated sustained functional and anatomic improvements in patients with wet age-related macular degeneration through 156 weeks, according to a ...

China’s NMPA approves Eylea 8 mg for wet age-related macular degeneration: Berlin Friday, May 23, 2025, 09:00 Hrs [IST] The Center for Drug Evaluation (CDE) of China’s National Medical Products ...

Bayer seeks EMA approval for aflibercept 8 mg for treatment of retinal vein occlusion: Berlin Thursday, April 10, 2025, 16:00 Hrs [IST] Bayer has submitted an application to the European Medicines ...

The U.S. Food and Drug Administration approved a higher dose version of Regeneron Pharmaceuticals' drug Eylea for treatment of a disease that is a leading cause of blindness among the elderly, the ...